Advances in Host-Directed Therapies Against Tuberculosis

Editors: Karakousis, Petros C, Hafner, Richard, Gennaro, Maria Laura (Eds.)

Free Preview
  • Host-directed therapy is a unique, innovative, and burgeoning new approach for the treatment of infectious diseases, and specifically for tuberculosis, the leading cause of death by a single infectious agent. As a new field, no similar comprehensive survey of completed and ongoing research exists
  • Each section of the text contains several chapters written by a top expert in that specific area. The information provided represents a thorough and state-of-the-art analysis of the field
  • The implications for host responses and pathways are of broad interest in physiology and in various diseases of non-infectious origin (e.g, autoimmunity, cancer, metabolic disorders), or those that can be exploited for treating infectious diseases other than tuberculosis
see more benefits

Buy this book

eBook 139,09 €
price for Spain (gross)
  • ISBN 978-3-030-56905-1
  • Digitally watermarked, DRM-free
  • Included format: EPUB, PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover 176,79 €
price for Spain (gross)
  • ISBN 978-3-030-56904-4
  • Free shipping for individuals worldwide
  • Institutional customers should get in touch with their account manager
  • Covid-19 shipping restrictions
  • Usually ready to be dispatched within 3 to 5 business days, if in stock
  • The final prices may differ from the prices shown due to specifics of VAT rules
About this book

This book discusses specific immune cell regulatory  pathway(s), immune cell types,  or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host-directed therapy (HDT). The pathways/mechanisms investigated are either protective – thus calling for pathway/factor enhancing drugs – or maladaptive – thus calling for pathway/factor inhibitory drugs. Discovery and development (pre-clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease-specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non-infectious diseases.

About the authors

Petros C. Karakousis, M.D., is an infectious diseases-trained physician scientist and Professor of Medicine at the Johns Hopkins University School of Medicine. His research focus is on host-pathogen interactions contributing to Mycobacterium tuberculosis persistence and antibiotic tolerance. His laboratory is actively investigating the repurposing of clinically available agents with immune-modulatory properties as adjunctive host-directed therapy, in order to shorten the duration of TB treatment and improve lung pathology.

Maria Laura Gennaro, M.D., is Professor of Medicine at Rutgers New Jersey School of Medicine. Her laboratory studies mechanisms of adaptation expressed by Mycobacterium tuberculosis and by the host macrophage during infection, with the goal of finding targets for therapeutic intervention. She has a specific interest in macrophage lipid metabolism, which is altered following M. tuberculosis infection, thereby promoting bacterial survival.

Richard Hafner, M.D., is an infectious diseases-trained physician and Chief of the TB Clinical Research Branch in the Division of AIDS at NIAID/NIH. Throughout his career, he has had a long-standing interest in advancing innovative host-directed therapies for infections. He has been involved in several clinical trials, authored various articles, and hosted multiple scientific meetings related to research to develop targeted HDTs for TB.

Table of contents (22 chapters)

Table of contents (22 chapters)
  • Introduction: An Overview of Host-Directed Therapies for Tuberculosis

    Pages 3-12

    Frank, Daniel J. (et al.)

  • Sirtuin Deacetylases: Linking Mycobacterial Infection and Host Metabolism

    Pages 15-26

    Smulan, Lorissa (et al.)

  • The Mammalian Target of Rapamycin Complex 1 (mTORC1): An Ally of M. tuberculosis in Host Cells

    Pages 27-40

    Bruiners, Natalie (et al.)

  • HIF-1α as a Potential Therapeutic Target for Tuberculosis Treatment

    Pages 41-59

    Jiang, Qingkui (et al.)

  • Nuclear Receptors in Host-Directed Therapies against Tuberculosis

    Pages 61-67

    Jo, Eun-Kyeong

Buy this book

eBook 139,09 €
price for Spain (gross)
  • ISBN 978-3-030-56905-1
  • Digitally watermarked, DRM-free
  • Included format: EPUB, PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover 176,79 €
price for Spain (gross)
  • ISBN 978-3-030-56904-4
  • Free shipping for individuals worldwide
  • Institutional customers should get in touch with their account manager
  • Covid-19 shipping restrictions
  • Usually ready to be dispatched within 3 to 5 business days, if in stock
  • The final prices may differ from the prices shown due to specifics of VAT rules
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
Advances in Host-Directed Therapies Against Tuberculosis
Editors
  • Petros C Karakousis
  • Richard Hafner
  • Maria Laura Gennaro
Copyright
2021
Publisher
Springer International Publishing
Copyright Holder
Springer Nature Switzerland AG
eBook ISBN
978-3-030-56905-1
DOI
10.1007/978-3-030-56905-1
Hardcover ISBN
978-3-030-56904-4
Edition Number
1
Number of Pages
XIII, 332
Number of Illustrations
20 b/w illustrations
Topics